Lv1
70 积分 2024-02-18 加入
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors
7天前
已完结
Pathology of IgA nephropathy: A global perspective
9天前
已完结
[The Japanese Clinical Guidelines 2022 for Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome: An Overview]
16天前
已完结
Characteristics and prognosis of near-fatal asthma exacerbations
16天前
已完结
Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype
17天前
已完结
Life Expectancy in Chronic Obstructive Pulmonary Disease
17天前
已完结
IgA Nephropathy in Adults
23天前
已完结
Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan
1个月前
已完结
Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
